NASDAQ : ABVX
ABIVAX Société Anonyme — Key statistics
Healthcare · Biotechnology · France
Last price 86.59 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.69B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.69B |
| Enterprise Value | 7.25B |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 21, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 79.82M |
| Shares Change (YoY) | +22.39% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 91.97% |
| Float | 71.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,442.83 |
| Forward PS | 2,701.25 |
| PB Ratio | 18.39 |
| P/TBV Ratio | 19.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1,358.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.97 |
| Quick Ratio | 5.79 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.35 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -252.35% |
| Return on Assets (ROA) | -62.88% |
| Return on Invested Capital (ROIC) | -87.55% |
| Return on Capital Employed (ROCE) | -74.95% |
| Weighted Average Cost of Capital (WACC) | 3.25% |
| Revenue Per Employee | $54,419 |
| Profits Per Employee | -$4.68M |
| Employee Count | 98 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.23 |
| 52-Week Price Change | -12.48% |
| 50-Day Moving Average | 100.14 |
| 200-Day Moving Average | 114.10 |
| Relative Strength Index (RSI) | 40.03 |
| Average Volume (20 Days) | 1,078,331 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.25M |
| Short Previous Month | 7.78M |
| Short % of Shares Out | 8.39% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.08 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.33M |
| Gross Profit | 5.33M |
| Operating Income | -334.40M |
| Pretax Income | -458.38M |
| Net Income | -458.38M |
| EBITDA | -333.08M |
| EBIT | -334.40M |
| Loss Per Share | -$5.80 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 459.71M |
| Total Debt | 1.38M |
| Net Cash | 458.32M |
| Net Cash Per Share | $5.74 |
| Equity (Book Value) | 418.45M |
| Book Value Per Share | 5.24 |
| Working Capital | 406.64M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -220.65M |
| Capital Expenditures | -274,388 |
| Depreciation & Amortization | 1.29M |
| Net Borrowing | -95.62M |
| Free Cash Flow | -220.93M |
| FCF Per Share | -$2.77 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -6,270.37% |
| Pretax Margin | -8,595.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.39% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.70% |
| FCF Yield | -2.87% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $163.58 |
| Price Target Difference | 88.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 319.59% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 37.68 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |